Phase 2 Study of ONC201 in Neuroendocrine Tumors
NCT03034200
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Neuroendocrine Tumor
Metastatic Neuroendocrine Tumor
Interventions
DRUG:
ONC201
Sponsor
Peter Anderson